Despite PD-1/PDL1 upregulation was found to antagonize the anti-tumor effects of the CSF1Ri, it may, at the same time, uncover a potential additional anti-tumor target since PDL1 expression is a classic marker of sensitivity in anti-PDL1 drugs [37]. The gene discussed is CD274; the disease is neoplasm.